Immuneed, a Swedish biotech service company, has appointed Charlotte Leife as the company’s new CEO.
The recruitment is a result of Immuneed’s rigorous growth and an important step in the company’s evolution into a global service provider. Immuneed will now focus on immuno-service and promotion of its unique human whole-blood loop assay.
The assay uses fresh, circulating blood with all blood components intact, to generate clinically relevant data for better understanding of first-in-man infusion reactions of biopharmaceuticals prior to clinical trial entry.
“After a comprehensive search process, the board is pleased to have found the best individual to assume leadership of Immuneed,” said Camilla Huse Bondesson, chairman of the board.
“Charlotte has been a successful commercial executive, translating scientific and commercial ideas into prosperous market launches for the biotechnology industry. This, combined with her high performance in building and leading strong teams, makes Charlotte the perfect choice to lead Immuneed.”
Leife holds a MSc degree in Chemistry and an executive MBA from Uppsala University. She has more than 25 years of experience in marketing, sales and management in the biotech and pharma industry. She has held leading positions at Baxter and Biogen as well served as chair of the board at the Swedish American Chamber of Commerce in Boston, New England (SACCNE).
Leife said: “I am thrilled to have been offered the opportunity to lead Immuneed at such an important time in its development. Since I get inspired by entrepreneurial environments with talented and dedicated professionals, Immuneed was a perfect match for me. The company has an innovative and powerful tool, which provides customers with unique and comprehensive whole blood data. I am looking forward to building on this success while ensuring we remain focused on delivering the very best service to our customers.”
Leife succeeds Gunilla Ekström, who assumes a CEO position at TET Pharma, a wholly owned daughter company founded by Immuneed to support a therapeutic cancer vaccine project based on the patented TET-technology.
